4 Stocks Pushing The Drugs Industry Higher

3. As of noon trading, BioMarin Pharmaceuticals (BMRN) is up $11.10 (29.7%) to $48.51 on heavy volume Thus far, 10.0 million shares of BioMarin Pharmaceuticals exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $45.99-$49.52 after having opened the day at $46.00 as compared to the previous trading day's close of $37.41.

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and rest of the world. BioMarin Pharmaceuticals has a market cap of $4.6 billion and is part of the health care sector. The company has a P/E ratio of -48.4, below the S&P 500 P/E ratio of 17.7. Shares are up 7.0% year to date as of the close of trading on Friday. Currently there are 13 analysts that rate BioMarin Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates BioMarin Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and increase in net income. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and feeble growth in the company's earnings per share. Get the full BioMarin Pharmaceuticals Ratings Report now.

« First ‹ Previous 1 2 3 4 Next › Last »

 

For more information on Novo Nordisk A/S click any of the following:

• Novo Nordisk A/S Stock Price

• Novo Nordisk A/S Analyst Ratings

• Novo Nordisk A/S Key Stats & Profile

• Novo Nordisk A/S Earnings

• Novo Nordisk A/S Ratio Comparison

• Novo Nordisk A/S Growth Rates

• Novo Nordisk A/S Balance Sheet

• Novo Nordisk A/S Cash Flow

• Novo Nordisk A/S Income Statement